INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 131 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $45,342 | +98.0% | 215,403 | +50.5% | 0.00% | – |
| Q1 2023 | $22,902 | -71.2% | 143,138 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $79,442 | -53.3% | 143,138 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $170,000 | +86.8% | 143,138 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $91,000 | -44.2% | 143,138 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $163,000 | -49.4% | 143,138 | 0.0% | 0.00% | -40.0% |
| Q4 2021 | $322,000 | -34.3% | 143,138 | 0.0% | 0.01% | -44.4% |
| Q3 2021 | $490,000 | +14.5% | 143,138 | 0.0% | 0.01% | +12.5% |
| Q2 2021 | $428,000 | -7.4% | 143,138 | 0.0% | 0.01% | -11.1% |
| Q1 2021 | $462,000 | +52.5% | 143,138 | 0.0% | 0.01% | +28.6% |
| Q4 2020 | $303,000 | +81.4% | 143,138 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $167,000 | +29.5% | 143,138 | 0.0% | 0.00% | +33.3% |
| Q2 2020 | $129,000 | +7.5% | 143,138 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $120,000 | -12.4% | 143,138 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $137,000 | -6.8% | 143,138 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $147,000 | -43.0% | 143,138 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $258,000 | +15.7% | 143,138 | +20.7% | 0.01% | +14.3% |
| Q1 2019 | $223,000 | +59.3% | 118,585 | 0.0% | 0.01% | +40.0% |
| Q4 2018 | $140,000 | -56.4% | 118,585 | 0.0% | 0.01% | -50.0% |
| Q3 2018 | $321,000 | +42.0% | 118,585 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $226,000 | -9.2% | 118,585 | 0.0% | 0.01% | -20.0% |
| Q1 2018 | $249,000 | +3.3% | 118,585 | 0.0% | 0.01% | +11.1% |
| Q4 2017 | $241,000 | +52.5% | 118,585 | 0.0% | 0.01% | +50.0% |
| Q3 2017 | $158,000 | -6.0% | 118,585 | +10.7% | 0.01% | 0.0% |
| Q2 2017 | $168,000 | -51.4% | 107,091 | 0.0% | 0.01% | -57.1% |
| Q1 2017 | $346,000 | +138.6% | 107,091 | 0.0% | 0.01% | +133.3% |
| Q4 2016 | $145,000 | -13.2% | 107,091 | 0.0% | 0.01% | -14.3% |
| Q3 2016 | $167,000 | +17.6% | 107,091 | 0.0% | 0.01% | +16.7% |
| Q2 2016 | $142,000 | -71.3% | 107,091 | +14.0% | 0.01% | -72.7% |
| Q1 2016 | $495,000 | -32.8% | 93,934 | 0.0% | 0.02% | -35.3% |
| Q4 2015 | $737,000 | -5.1% | 93,934 | +2.2% | 0.03% | -8.1% |
| Q3 2015 | $777,000 | -22.8% | 91,900 | 0.0% | 0.04% | -17.8% |
| Q2 2015 | $1,006,000 | -21.7% | 91,900 | 0.0% | 0.04% | -23.7% |
| Q1 2015 | $1,285,000 | -17.2% | 91,900 | 0.0% | 0.06% | -23.4% |
| Q4 2014 | $1,552,000 | +71.5% | 91,900 | +36.4% | 0.08% | +71.1% |
| Q3 2014 | $905,000 | +5.4% | 67,400 | 0.0% | 0.04% | +2.3% |
| Q2 2014 | $859,000 | +7.2% | 67,400 | 0.0% | 0.04% | -2.2% |
| Q1 2014 | $801,000 | -14.0% | 67,400 | 0.0% | 0.04% | -11.8% |
| Q4 2013 | $931,000 | -20.8% | 67,400 | 0.0% | 0.05% | -23.9% |
| Q3 2013 | $1,175,000 | +7.7% | 67,400 | 0.0% | 0.07% | +8.1% |
| Q2 2013 | $1,091,000 | – | 67,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |